Aliyev, V.; Guliyev, M.; Günaltılı, M.; Fidan, M.C.; Çerme, E.; Abbasov, H.; Birsin, Z.; Cebeci, S.; Demirci, N.S.; Alan, Ö.
Comparative Efficacy and Cost-Effectiveness of Denosumab Versus Zoledronic Acid in Cancer Patients with Bone Metastases. J. Clin. Med. 2025, 14, 6469.
https://doi.org/10.3390/jcm14186469
AMA Style
Aliyev V, Guliyev M, Günaltılı M, Fidan MC, Çerme E, Abbasov H, Birsin Z, Cebeci S, Demirci NS, Alan Ö.
Comparative Efficacy and Cost-Effectiveness of Denosumab Versus Zoledronic Acid in Cancer Patients with Bone Metastases. Journal of Clinical Medicine. 2025; 14(18):6469.
https://doi.org/10.3390/jcm14186469
Chicago/Turabian Style
Aliyev, Vali, Murad Guliyev, Murat Günaltılı, Mehmet Cem Fidan, Emir Çerme, Hamza Abbasov, Zeliha Birsin, Selin Cebeci, Nebi Serkan Demirci, and Özkan Alan.
2025. "Comparative Efficacy and Cost-Effectiveness of Denosumab Versus Zoledronic Acid in Cancer Patients with Bone Metastases" Journal of Clinical Medicine 14, no. 18: 6469.
https://doi.org/10.3390/jcm14186469
APA Style
Aliyev, V., Guliyev, M., Günaltılı, M., Fidan, M. C., Çerme, E., Abbasov, H., Birsin, Z., Cebeci, S., Demirci, N. S., & Alan, Ö.
(2025). Comparative Efficacy and Cost-Effectiveness of Denosumab Versus Zoledronic Acid in Cancer Patients with Bone Metastases. Journal of Clinical Medicine, 14(18), 6469.
https://doi.org/10.3390/jcm14186469
